Amrize Ltd Stock 12‑Month Price Target Cut to $52.04, Implies 39% Upside

Amrize Ltd's average stock price target was reduced from $52.37 to $52.04 by 24 analysts, with a range of $40 to $65. This implies a 39% upside from the September 30 closing price. The consensus rating remains 'Buy' among 28 analysts.

Original reporting
Published Oct 1, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 10:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Amrize Ltd Stock 12‑Month Price Target Cut to $52.04, Implies 39% Upside — source image
Decision brief

The 30-second read

Med
01

Why it matters

The modest target reduction suggests a slight bearish tilt but retains upside expectations.

02

Market read

Minor analyst target adjustment for a micro‑cap; limited immediate market impact.

03

What to watch

Potential upcoming product launches or market catalysts not reflected in the target.

Relevance 6/10Novelty 6/10Timing: immediate

Background

Analyst consensus price target for Amrize Ltd was lowered slightly, maintaining a Buy rating.

Market effects

None

None

None

Counterpoint

The price target cut may be overly cautious given the stock's upside potential.

Key entities

  • Amrize Ltd

    Subject of the price target revision.

Related articles

Low

Amrize (SWX:AMRZ) Reshuffles Building Envelope Leadership As Fair Value Stays In Focus

Amrize (SWX:AMRZ) appointed Mario Gross as President of its Building Envelope division following Jake Gosa's resignation. The company's shares trade at CHF32.07, down 15.3% over the past month and 28.5% over the last quarter. Analysts suggest a fair value of CHF46.66, citing potential earnings power and margin expansion from the ASPIRE synergy program. The P/E ratio is 17.3x, compared to an estimated fair ratio of 30.5x and a peer average of 48.6x.

High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

$AMRZMed

BofA downgrades Amrize stock on growth concerns, cuts price target to $40

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.

High

Why is Amrize stock sliding today?

Amrize AG (AMRZ) fell 2.9% to CHF 34.13 after JPMorgan downgraded it to Neutral, citing executive departures and missed earnings. The stock hit a 52-week low of CHF 33.64, with JPMorgan lowering its price target to $52 from $57. The broader market showed no significant movement, indicating the decline is company-specific.